Filing Flows › Bio-Rad Laboratories (BIO) › Guidance & outlook
Bio-Rad Laboratories (BIO) guidance and outlook
Bio-Rad Laboratories (BIO) reaffirmed its guidance on Nov 4, 2026: Operating margin 10%–12% for FY2026. Bio-Rad Laboratories' 10-Q filed Nov 4, 2026 makes 3 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +3% | reaffirmed |
| Operating margin | FY2026 | 10%–12% | reaffirmed |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- We expect these conditions to continue to affect our business.
- These disruptions impacted our results during the first nine months of 2026 and, given the continued uncertainty regarding the duration and scope of the conflict, we expect these conditions to continue to adversely affect the EMEA region for the remainder of 2026.
- We expect to incur total pre-tax costs of approximately $80 million to $90 million, which consist primarily of one-time termination benefits, including cash severance payments, healthcare benefits, and related transition assistance.
Bio-Rad Laboratories' latest quarter
Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Bio-Rad Laboratories raise or lower its guidance?
Bio-Rad Laboratories (BIO) reaffirmed its guidance on Nov 4, 2026: Operating margin 10%–12% for FY2026.
What does Bio-Rad Laboratories expect?
We expect these conditions to continue to affect our business. These disruptions impacted our results during the first nine months of 2026 and, given the continued uncertainty regarding the duration and scope of the conflict, we expect these conditions to continue to adversely affect the EMEA region for the remainder of 2026. We expect to incur total pre-tax costs of approximately $80 million to $90 million, which consist primarily of one-time termination benefits, including cash severance payments, healthcare benefits, and related transition assistance.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.